Sanofi

4Q Revenues: €11.3 billion +7%

4Q Loss: €801 million -261%

FY Revenues: €43.6 billion +6%

FY Earnings:  €7.8 billion +41%

Comments: Dupixent sales were €4.2 billion in the quarter, up 32%. Lantus sales were €419 million, up 1%. Toujeo sales were €332 million, up 19%. Fabrazyme sales were €252 million, down 1%. Plavix sales were up 7.6% to €214 million in the quarter. Lovenox sales were $179 million, down 21.6% impacted by increasing competition. Cerezyme sales were €171 million up 3%. The Gaucher disease franchise (Cerezyme and Cerdelga) sales were €254 million and increased by 1.6%. Alprolix sales were €149 million, down 4%.

Vaccine sales were down 2.5% in the quarter to €2.0 billion. Beyfortus sales were down 15% to €686 million. Influenza, COVID-19 vaccines sales were up 31.5 % to €575 million in the quarter. Polio/Pertussis/Hib (PPH) primary and booster vaccines sales were €551 million down 9.5%. Meningitis, travel, and endemic vaccines sales were €227 million, down 5%.

*Changes in net sales are at constant exchange rates (CER).